Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agrostis gigantea pollen allergen extract, also known as Redtop grass pollen extract, is a biological product used for the diagnosis and treatment of Type I hypersensitivity reactions (allergies) to this specific grass. [17, 11] It is administered for diagnostic purposes via skin prick or intradermal tests to confirm sensitivity. [3, 4] For therapeutic use, it is a key component of allergen immunotherapy, available as subcutaneous injections (allergy shots) or sublingual drops/tablets. [10, 16] The goal of immunotherapy is to induce immune tolerance by gradually exposing the body to increasing doses of the allergen. [16] This process modulates the immune response, shifting it from a pro-allergic Th2-dominant profile to a more tolerant state, characterized by the production of blocking IgG antibodies and a reduction in allergen-specific IgE levels, thereby alleviating symptoms of allergic rhinitis (hay fever), allergic conjunctivitis, and allergic asthma upon natural exposure. [12, 16]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agrostis gigantea pollen allergen extract.